MX2022009517A - Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos. - Google Patents

Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos.

Info

Publication number
MX2022009517A
MX2022009517A MX2022009517A MX2022009517A MX2022009517A MX 2022009517 A MX2022009517 A MX 2022009517A MX 2022009517 A MX2022009517 A MX 2022009517A MX 2022009517 A MX2022009517 A MX 2022009517A MX 2022009517 A MX2022009517 A MX 2022009517A
Authority
MX
Mexico
Prior art keywords
nash
biomarkers
nonalcoholic steatohepatitis
subject
hepatic
Prior art date
Application number
MX2022009517A
Other languages
English (en)
Inventor
Stuart Field
Leigh Alexander
Rachel Ostroff
Original Assignee
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Operating Co Inc filed Critical Somalogic Operating Co Inc
Publication of MX2022009517A publication Critical patent/MX2022009517A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

Se proporcionan métodos, composiciones y kits para determinar si un sujeto tiene una afección hepática, lo cual incluye esteatosis hepática, inflamación hepática, balonamiento hepatocelular y/o fibrosis hepática. En diversas modalidades, la afección hepática del sujeto incluye esteatohepatitis no alcohólica (NASH).
MX2022009517A 2020-02-10 2021-02-09 Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos. MX2022009517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
PCT/US2021/017217 WO2021163034A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
MX2022009517A true MX2022009517A (es) 2022-09-02

Family

ID=74858782

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009517A MX2022009517A (es) 2020-02-10 2021-02-09 Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230071234A1 (es)
EP (1) EP4103948A1 (es)
JP (1) JP2023512701A (es)
KR (1) KR20220140727A (es)
CN (1) CN115066616A (es)
AU (1) AU2021220787A1 (es)
BR (1) BR112022015303A2 (es)
CA (1) CA3166923A1 (es)
IL (1) IL295064A (es)
MX (1) MX2022009517A (es)
WO (1) WO2021163034A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008156662A1 (en) * 2007-06-14 2008-12-24 George Mason Intellectual Properties, Inc. Methods of diagnosing non-alcoholic steatohepatitis (nash)
EP2336314A1 (en) 2007-07-17 2011-06-22 Somalogic, Inc. Improved selex and photoselex
US20130116150A1 (en) 2010-07-09 2013-05-09 Somalogic, Inc. Lung Cancer Biomarkers and Uses Thereof
AU2011312491B2 (en) 2010-09-27 2015-06-04 Somalogic, Inc. Mesothelioma biomarkers and uses thereof
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
JP2018518169A (ja) * 2015-06-05 2018-07-12 レグルス セラピューティクス インコーポレイテッド 非アルコール性脂肪肝疾患バイオマーカー
CN115015552A (zh) * 2015-06-19 2022-09-06 赛拉预测公司 用于预测早产的生物标志物对
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
JP2023512701A (ja) 2023-03-28
IL295064A (en) 2022-09-01
EP4103948A1 (en) 2022-12-21
KR20220140727A (ko) 2022-10-18
CA3166923A1 (en) 2021-08-19
WO2021163034A1 (en) 2021-08-19
BR112022015303A2 (pt) 2022-09-27
US20230071234A1 (en) 2023-03-09
AU2021220787A1 (en) 2022-09-01
CN115066616A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
WO2008010864A3 (en) Modified adenovirus hexon protein and uses thereof
TW200603813A (en) Cyclic progestin regimens and kits
WO2007040862A3 (en) System and method for determining a presence state of a user
TW200738456A (en) Carpet waste composite
MX360140B (es) Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos.
WO2005047524A3 (en) Compositions and methods for inducing cell dedifferentiation
MX2022009517A (es) Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos.
WO2005098711A3 (en) Improving advertisement approval
TW200519569A (en) Cold plate
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
HK1079822A1 (en) Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
WO2006096735A3 (en) Enhancing a luminescent signal
BRPI0407637A (pt) método e equipamento para estabelecer sessão de comunicação com convite prévio
AU2002241160A1 (en) Lipid profile modulation with steroids
MY150643A (en) Methods and compositions for targeting hepsin
GB2446336A (en) High speed interconnect
WO2001089225A3 (en) Image foreground/background velocity detector
EP1127580A3 (en) Method of increasing the bioavailability and tissue penetration of azithromycin
WO2007024762A3 (en) Lined envelope
TW200716130A (en) Purified form of tanaproget
WO2006086285A3 (en) Hot content update for a target device
WO2006124872A3 (en) Methods for determining contamination of fluid compositions
GB2407519A (en) Hybrid golf club shaft set
WO2021231606A3 (en) Modified guide rnas for crispr genome editing
WO2005073254A3 (en) Methods for inhibiting squamous cell carcinoma using antibodies against laminin